Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR has informed that Emergency Use Authorisation for the Merck drug Molnupiravir, which is an oral antiviral medicine for the treatment of mild-to-moderate COVID-19 could be cleared for use in a few days’ time.
The medicine is meant for adults who are at risk for progressing to severe COVID-19 or hospitalization. Another pill from Pfizer, Paxlovid, may take some more time.
“The two drugs will make a difference and as we move from pandemic to endemic, these are the ones which are going to be more important than vaccination,” he said.
Calling the drugs the “final nail in the coffin of the virus by science”, he said, “I think Molnupiravir will be already available to us. Five companies are sitting with the drug manufacturer… I think any day we will have approval of Molnupiravir”.
“Data for Molnupiravir has been “sitting with the regulator” here before the UK regulator’s approval,” he said. “So already SECs are looking at it. And I think they will they will get faster approval now. And therefore, it would it be safe to say that within the next one month, there would be a decision on approval for the Merck drug”.
Pfizer has said according to clinical trial, Paxlovid cuts the risk of hospitalization or death by 89 per cent in vulnerable adults.
Merck has already contracted five companies and has given this license to them. Pfizer is also likely to do the same because it will have to utilize the Indian capacity to manufacture the drugs that are required for the global use.
“The cost will be far lower than the 700 dollars that’s being considered in the US for the Merck vaccine because in America it is costly for various other reasons and not for the manufacturing cost,” Dr Vishwakarma said.
